Screener
Beam Therapeutics BEAM Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (See Note 7, License and other agreements and Note 8, Collaboration and license agreements) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.01 par value; 250,000,000 shares authorized, 102,741,848 and 101,748,962 issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 1,027 | 1,017 |
| Additional paid-in capital | 2,900,018 | 2,877,449 |
| Accumulated other comprehensive (loss) income | (1,070) | 1,111 |
| Accumulated deficit | (1,735,537) | (1,641,219) |
| Total stockholders’ equity | 1,164,438 | 1,238,358 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's common stock?
- Beam Therapeutics (BEAM) reported common stock of $1.03M in Q1 2026.
- How has Beam Therapeutics's common stock changed year-over-year?
- Beam Therapeutics's common stock increased by 2.1% year-over-year, from $1.01M to $1.03M.
- What is the long-term trend for Beam Therapeutics's common stock?
- Over 5 years (2020 to 2025), Beam Therapeutics's common stock has grown at a 12.2% compound annual growth rate (CAGR), from $573K to $1.02M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Beam Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude